NGEN.V - NervGen Pharma Corp.

TSXV - TSXV Real Time Price. Currency in CAD
Currency in CAD

Valuation Measures4

Market Cap (intraday) 101.84M
Enterprise Value 84.08M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)10.31
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -4.25

Trading Information

Stock Price History

Beta (5Y Monthly) 1.73
52-Week Change 3-12.69%
S&P500 52-Week Change 36.21%
52 Week High 32.6000
52 Week Low 31.5000
50-Day Moving Average 31.6652
200-Day Moving Average 31.7943

Share Statistics

Avg Vol (3 month) 320.95k
Avg Vol (10 day) 313.83k
Shares Outstanding 559.21M
Implied Shares Outstanding 6N/A
Float 846.3M
% Held by Insiders 121.65%
% Held by Institutions 10.01%
Shares Short (May 30, 2023) 41.72k
Short Ratio (May 30, 2023) 40.08
Short % of Float (May 30, 2023) 4N/A
Short % of Shares Outstanding (May 30, 2023) 40.00%
Shares Short (prior month Apr 27, 2023) 42.8k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2022
Most Recent Quarter (mrq)Mar 30, 2023


Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-86.14%
Return on Equity (ttm)-180.65%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -22.69M
Net Income Avi to Common (ttm)-20.46M
Diluted EPS (ttm)-0.3600
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)18.02M
Total Cash Per Share (mrq)0.3
Total Debt (mrq)262.37k
Total Debt/Equity (mrq)2.66
Current Ratio (mrq)2.04
Book Value Per Share (mrq)0.17

Cash Flow Statement

Operating Cash Flow (ttm)-18.34M
Levered Free Cash Flow (ttm)-3.65M